Matthew Dixon1,2, Alyson L Mahar3,2, Lucy K Helyer4, Jovanka Vasilevska-Ristovska2, Calvin Law2,5,6,7, Natalie G Coburn8,9,10,11. 1. Department of Surgery, Maimonides Medical Center, Brooklyn, NY, USA. 2. Division of Surgical Oncology, Odette Cancer Centre, Sunnybrook Health Sciences Centre, Sunnybrook Research Institute, Suite T2-60, 2075 Bayview Ave, Toronto, ON, M4N 3M5, Canada. 3. Department of Public Health Sciences, Queen's University, Kingston, ON, Canada. 4. Department of Surgery, Dalhousie University, Halifax, NS, Canada. 5. Department of Surgery, University of Toronto, Toronto, ON, Canada. 6. Insitute of Health Policy, Management and Evaluation, University of Toronto, Toronto, ON, Canada. 7. Institute for Clinical Evaluative Sciences, Toronto, ON, Canada. 8. Division of Surgical Oncology, Odette Cancer Centre, Sunnybrook Health Sciences Centre, Sunnybrook Research Institute, Suite T2-60, 2075 Bayview Ave, Toronto, ON, M4N 3M5, Canada. natalie.coburn@sunnybrook.ca. 9. Department of Surgery, University of Toronto, Toronto, ON, Canada. natalie.coburn@sunnybrook.ca. 10. Insitute of Health Policy, Management and Evaluation, University of Toronto, Toronto, ON, Canada. natalie.coburn@sunnybrook.ca. 11. Institute for Clinical Evaluative Sciences, Toronto, ON, Canada. natalie.coburn@sunnybrook.ca.
Abstract
BACKGROUND: Stage IV gastric cancer is lethal, and little population-based research on prognostic factors has been performed in low-incidence countries. Therefore, we investigated the consistency of the associations of patient, disease and healthcare system factors identified in previous population-based research to understand their generalizability to other low-incidence populations. METHODS: A population-based, retrospective cohort study of patients diagnosed with Stage IV gastric cancer in Ontario between 1 April 2005 and 31 March 2008 was performed. Kaplan-Meier methodology and the log-rank test were used for bivariate analysis. Multivariate Cox proportional hazard regression was performed. Hazard ratios (HRs) and 95% confidence intervals (CIs) are presented. RESULTS: On multivariate analysis, patient, disease and healthcare system factors were independent predictors of survival. Increasing age per 10 years (HR 1.07; 95% CI 1.02-1.10), a tumor located in the gastroesophageal junction (HR 1.09; 95% CI 0.94-1.27) or middle of the stomach (HR 1.14; 95% CI 0.97-1.35), presence of carcinomatosis (HR 1.61; 95% CI 1.42-1.83) and a larger burden of metastatic disease (2-3 sites of metastatic disease: HR 1.17; 95% CI 1.03-1.32; ≥ 4 sites: HR 1.69; 95% CI 1.30-2.20) were associated with worse prognosis. Female gender, receipt of surgery, chemotherapy and radiotherapy and treatment from a high-volume, gastric cancer specialist were all associated with significantly better prognosis. In addition, there was evidence of significant geographic variation in survival. CONCLUSION: This study provides supporting evidence for patient, disease and healthcare system prognostic factors in metastatic gastric cancer. Future work investigating the role of emerging molecular and biologic information will need to take these established prognostic factors into consideration.
BACKGROUND: Stage IV gastric cancer is lethal, and little population-based research on prognostic factors has been performed in low-incidence countries. Therefore, we investigated the consistency of the associations of patient, disease and healthcare system factors identified in previous population-based research to understand their generalizability to other low-incidence populations. METHODS: A population-based, retrospective cohort study of patients diagnosed with Stage IV gastric cancer in Ontario between 1 April 2005 and 31 March 2008 was performed. Kaplan-Meier methodology and the log-rank test were used for bivariate analysis. Multivariate Cox proportional hazard regression was performed. Hazard ratios (HRs) and 95% confidence intervals (CIs) are presented. RESULTS: On multivariate analysis, patient, disease and healthcare system factors were independent predictors of survival. Increasing age per 10 years (HR 1.07; 95% CI 1.02-1.10), a tumor located in the gastroesophageal junction (HR 1.09; 95% CI 0.94-1.27) or middle of the stomach (HR 1.14; 95% CI 0.97-1.35), presence of carcinomatosis (HR 1.61; 95% CI 1.42-1.83) and a larger burden of metastatic disease (2-3 sites of metastatic disease: HR 1.17; 95% CI 1.03-1.32; ≥ 4 sites: HR 1.69; 95% CI 1.30-2.20) were associated with worse prognosis. Female gender, receipt of surgery, chemotherapy and radiotherapy and treatment from a high-volume, gastric cancer specialist were all associated with significantly better prognosis. In addition, there was evidence of significant geographic variation in survival. CONCLUSION: This study provides supporting evidence for patient, disease and healthcare system prognostic factors in metastatic gastric cancer. Future work investigating the role of emerging molecular and biologic information will need to take these established prognostic factors into consideration.
Authors: Dongyun Yang; Andrew Hendifar; Cosima Lenz; Kayo Togawa; Felicitas Lenz; Georg Lurje; Alexandra Pohl; Thomas Winder; Yan Ning; Susan Groshen; Heinz-Josef Lenz Journal: J Gastrointest Oncol Date: 2011-06
Authors: Lee J McGhan; Barbara A Pockaj; Richard J Gray; Sanjay P Bagaria; Nabil Wasif Journal: J Gastrointest Surg Date: 2011-10-05 Impact factor: 3.452
Authors: Jillian K Smith; Joshua S Hill; Sing Chau Ng; Theodore P McDade; Shimul A Shah; Jennifer F Tseng Journal: J Gastrointest Surg Date: 2010-09-09 Impact factor: 3.452
Authors: Pamela L Kunz; Matthew Gubens; George A Fisher; James M Ford; Daphne Y Lichtensztajn; Christina A Clarke Journal: J Clin Oncol Date: 2012-09-04 Impact factor: 44.544
Authors: Alicia S Borggreve; Lucas Goense; Hylke J F Brenkman; Stella Mook; Gert J Meijer; Frank J Wessels; Marcel Verheij; Edwin P M Jansen; Richard van Hillegersberg; Peter S N van Rossum; Jelle P Ruurda Journal: Br J Radiol Date: 2019-03-05 Impact factor: 3.039
Authors: Alyson L Mahar; Brandon Zagorski; Daniel Kagedan; Matthew Dixon; Abraham El-Sedfy; Jovanka Vasilevska-Ristovska; Daniela Cortinovis; Corwyn Rowsell; Calvin Law; Lucy Helyer; Lawrence Paszat; Natalie Coburn Journal: Can J Public Health Date: 2018-08-08
Authors: D J Kagedan; M E Dixon; R S Raju; Q Li; M Elmi; E Shin; N Liu; A El-Sedfy; L Paszat; A Kiss; C C Earle; N Mittmann; N G Coburn Journal: Curr Oncol Date: 2016-10-25 Impact factor: 3.677
Authors: Daniel J Kagedan; Ravish S Raju; Matthew E Dixon; Elizabeth Shin; Qing Li; Ning Liu; Maryam Elmi; Abraham El-Sedfy; Lawrence Paszat; Alexander Kiss; Craig C Earle; Nicole Mittmann; Natalie G Coburn Journal: HPB (Oxford) Date: 2016-02-09 Impact factor: 3.647
Authors: Julie Hallet; Nicole J Look Hong; Victoria Zuk; Laura E Davis; Vaibhav Gupta; Craig C Earle; Nicole Mittmann; Natalie G Coburn Journal: Gastric Cancer Date: 2019-12-13 Impact factor: 7.370
Authors: Ho Seok Seo; Kyo Young Song; Yoon Ju Jung; Seung Man Park; Hae Myung Jeon; Wook Kim; Hyung Min Chin; Jin-Jo Kim; Sung Keun Kim; Kyung Hwa Chun; Jeong Goo Kim; Jun Hyun Lee; Han Hong Lee; Dong Jin Kim; Han Mo Yoo; Chang Hyun Kim; Eun Young Kim; Cho Hyun Park Journal: World J Surg Date: 2018-10 Impact factor: 3.352